Engaging, commanding and always provocative, Lorraine uses stories and case examples, underpinned by data, to challenge industry icons and myths, offering creative approaches to solving intractable problems in life sciences and healthcare.
In this lively session based on real-life stories of successful innovation, you will learn “the art of the pivot—you never fail as long as you’re learning.”
Imagine this: It’s 1975. You’re 12 years old, sitting in a red booth in a diner with your dad and brother. Dad observes that some tables are cleared faster than others, then he challenges you to identify why and come up with at least 3 fixes. You and your brother see the cause for delay is most often half-opened sugar packets, their contents spilled all over the place. Together you devise a dozen solutions, deciding the best is a container shaped like a cube specifically designed to collect the used sugar packets – the sugar cube! That diner uses your model, and you sell it to other local restaurants too!
Fast forward to the 1990s. You’re working for a pharmaceutical company seeking to create a product for the debilitating gastrointestinal illness, Crohn’s disease – no treatment advances in over 40 years. Your scientists have created a new and stunning solution. However, the FDA is blocking progress for safety concerns; this technology is too radically new to accept that previous standards for clinical trials will be adequate. However, you (and your company) don’t say “Well, those are the rules; we can’t break them, so let’s cut our losses.” You pivot, exploring every “what-if” and reframing strategy.
Learn the genius in making big problems small including 3 very basic steps to the secret of innovating without failure:
- Break down your large problem into smaller and smaller groups of steps. Divide and conquer, assigning each small obstacle to those with the talents most suited to handle them.
- Devise several solutions for each of those small obstacles, realizing you’ll have to go through one or several options before you find your best one. Options that aren’t the best are not failures. They’re just not your best options. Pivot as often as necessary to stay on track.
- Pick the best options, assemble your solutions, and enjoy the journey.
This session explores novel approaches to addressing the four pillars in the healthcare ecosystem:
- Increasing the ability of patients to access care
- Improving the quality of care delivered and patient outcomes
- Making healthcare more efficient and affordable and
- Leveraging continuous innovation and learning to create sustainable healthcare models.
We will examine how the private sector is deploying innovative healthcare financing models, applying technology and evolving the role of patient centricity to address healthcare deficiencies in developed and underserved nations. Increasingly, private/public partnerships with an entrepreneurial mindset are emerging as a best practices model to improving healthcare in developing countries and the course will explore how these models operate. The role of key stakeholders in designing and implementing healthcare strategies will be studied including the role of providers/hospitals/healthcare systems; payors both private and public; manufacturers including biopharma, device and digital; and patient organizations. Woven throughout the course will be an examination of novel strategies for addressing chronic diseases, rare and orphan diseases and infectious diseases.
This session will examine how the new global healthcare paradigm — “value beyond the pill” — and improved patient outcomes, is forcing pharma to redefine value by providing customized services, information, communications and education to physicians, patients and payers.
Discussion will focus on how and why digital technologies are critical to the new pharma business model, and how these technologies are enabling pharma to achieve growth goals for their drug portfolios. In the process, we will illuminate how technologies are improving diagnosis, treatment, disease monitoring, patient compliance/adherence, and evaluate how technology is accelerating time to market and differentiating the winners from the laggards in terms of commercial success.
With the input of senior leaders, we will gain crucial insights about the portfolio approach pharma innovators are applying to their technology investments, and learn how company’s evolving business models are impelling business leaders to integrate digital into their solutions.
This session will examine the major forces in the dynamic global healthcare landscape and why pharma is re-examining its business model and how it engages with customers and stakeholders.
We will review categories of innovation: incremental, breakthrough and disruptive, and analyze the underpinnings of each and why pharma is applying a portfolio approach to its technology investments.
Case studies and examples of pharma investments in imaging, virtual reality, mobile, telemedicine and big data/analytics and its partnerships with technology companies such as Alphabet, Apple, IBM Watson and Qualcomm will provide rich and tangible evidence of how the new business models work and the impact on patients, physicians and payers. Attendees will benefit from the perspective of a senior healthcare executives, as we evaluate investments/partnerships their companies are making in digital innovation.
Recent advances in genomics, imaging, and biomarkers are translating into the development and uses of precision medicine—treatments that target specific pathways to modify the course of disease in specific populations, improving therapy effectiveness and reducing adverse side effects. This paradigm shift is having a resounding impact on patients and transforming all aspects of the healthcare system. Challenges remain on how to operationalize these new models and ensure their positive impact on business decision making and health economics.
In this session, we will examine a framework for understanding the unique challenges associated with precision medicine including cost, clinical decision making, patient privacy, and the competing roles of multiple stakeholders. We will review case studies for insights into the lessons learned on obtaining optimal business value from precision medicine. Finally, we will examine recommendations for how precision medicine may achieve its full potential for healthcare in the future.
Case studies include: 23andme, Patients Like Me, the NIH All of Us, Regeneron Genetics Institute, Flatiron Health and others.
Global healthcare system is transforming from volume to value. Moving from market of individual players incentivized by volume or activity to a system focused on improving collective value and team outcomes. This shift requires real world data to catalyze a system wide movement toward enhanced population health outcomes. New cost-effective ways are emerging to support the increasingly complex demands for real-world evidence by regulators, payers, and providers. These advances allow medical technology companies of any size to provide the most compelling support while tapping into advances involving secondary data and analytics. Real world data is patient healthcare status or delivery of health routinely collected from a variety of sources.
This session will examine how real world evidence is supporting value creation for companies and how they are engaging regulators, payers, providers and patients in the generation of real world evidence. We will
evaluate case studies of how real world data is being used by companies to: understand a rare disease for which there is little clinical data; accelerate patient recruitment; identify sub populations who will respond to a therapy; provide evidence and justification for new therapies and at a reasonable cost.